Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
J Med Chem ; 60(13): 5927-5932, 2017 07 13.
Article in English | MEDLINE | ID: mdl-28586211

ABSTRACT

A series of N-(3-((1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides were designed as the first class of highly selective ZAK inhibitors. The representative compound 3h strongly inhibits the kinase activity of ZAK with an IC50 of 3.3 nM and dose-dependently suppresses the activation of ZAK downstream signals in vitro and in vivo, while it is significantly less potent for the majority of 403 nonmutated kinases evaluated. Compound 3h also exhibits orally therapeutic effects on cardiac hypertrophy in a spontaneous hypertensive rat model.


Subject(s)
Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Protein Kinases/metabolism , Sulfonamides/chemistry , Sulfonamides/pharmacology , Animals , Cardiomegaly/drug therapy , Cardiomegaly/metabolism , Drug Design , Humans , MAP Kinase Kinase Kinases , Molecular Docking Simulation , Protein Kinase Inhibitors/therapeutic use , Rats, Inbred SHR , Rats, Inbred WKY , Sulfonamides/therapeutic use , Benzenesulfonamides
SELECTION OF CITATIONS
SEARCH DETAIL
...